MetaboSign
MetaboSign is a platform specialized in the analysis of bioenergetic signatures, diagnostics, and the development of new therapeutic molecules. It is equipped with a Seahorse XFe96 (Agilent) and possesses expertise in energy metabolism applied to fundamental and clinical research. It offers a variety of studies under normal or pathological conditions across a broad spectrum of models: immune cells (T lymphocytes, neutrophils, monocytes, NK cells) and glial cells (astrocytes, microglia), hIPS cells, fibroblasts, as well as small-animal models such as C. elegans and zebrafish, in vitro models (mice, rats), and analyses of large human cohorts. Under development since 2023, MetaboSign has established itself as a leader in the field of bioenergetics, particularly in the areas of immunometabolism and neurodevelopment.
© Inserm Umr1141
MetaboSign offers customized analyses or multimodal packages, tailored to both collaborative projects and competitive grant proposals (Horizon Europe, ERC, PEPR, ANR, international collaborations).
Our services combine:
- Standard and multimodal Seahorse analysis
- Spectral cytometry (NeuroDiderot) with panels of >35 immunological, metabolic, and mitochondrial markers
- Multimodal packages integrating immunology, energy metabolism, and neurodevelopment
Contact
Plateforme MetaboSign – NeuroDiderot
Scientific head: Dr Mireille Laforge, mireille.laforge@inserm.fr
Operational manager: Julien Pansiot, Julien.pansiot@inserm.fr
À lire aussi
[World Mental Health Day] At UMR 1141 NeuroDiderot: Shedding Light on and Transforming Mental Health
Under the direction of Pierre Gressens, the NeuroDiderot Joint Research Unit (UMR 1141) (Université Paris Cité and Inserm) is revolutionizing our understanding of neurodevelopmental and psychiatric disorders. By exploring early brain mechanisms and chronobiology,...
Conference Postponed Alexandra Benchoua from I-Stem : Human pluripotent stem cell models for high-throughput screening of therapeutic molecules and precision medicine in neurodevelopmental disorders.
Meeting Room 6th floor Bingen Building and Visio https://u-paris.zoom.us/j/84730677369?pwd=AFdhdI6alNWLbXub7sM1DJ33yUIOYN.1 - Summary séminaire A-Benchoua _27-nov-2025 english
New Golgipathy identified in NeuroDev team
The NeuroDev team publishes an article in Life Science Alliance [1] identifying the first human pathogenic variant of GORASP1, the gene encoding the Golgi stacking protein GRASP65, and demonstrating its consequences on glycosylation and mitotic progression. [1] S....
Job opportunity within The Integrative Genomics in Neurodevelopment group
The Integrative Genomics in Neurodevelopment group is seeking a highly motivated post-doctoral researcher. Check out the opportunity here: Post-doc researcher position in Computational Biology